84951-58-6

Basic information

• Product Name: 2-cyano-N-(pyridin-2-ylmethyl)acetamide
• Synonyms: 2-cyano-N-(pyridin-2-ylmethyl)acetamide;2-cyano-N-(2-pyridylmethyl)acetamide;2-cyano-N-(pyridin-2-ylmethyl)ethanamide;IDI1_030933;IVK/9350618;Maybridge4_000351;Oprea1_493131;SR-01000634156-1
• CAS NO: 84951-58-6
• Molecular Formula: C₉H₉N₃O
• Molecular Weight: 175.18726
• Mol File: 84951-58-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-cyano-N-(pyridin-2-ylmethyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyano-N-(pyridin-2-ylmethyl)acetamide(84951-58-6)
• EPA Substance Registry System: 2-cyano-N-(pyridin-2-ylmethyl)acetamide(84951-58-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 84951-58-6(Hazardous Substances Data)

Upstream product

• 504-29-0 2-aminopyridine 
• 105-34-0 methyl 2-cyanoacetate 
• 3731-51-9 2-(Aminomethyl)pyridine 
• 372-09-8 cyanoacetic acid 

Downstream Products

• 1352550-13-0 (E)-2-cyano-3-(4-hydroxyphenyl)-N-(pyridin-2-ylmethyl)acrylamide 
• 1352550-21-0 (E)-2-cyano-3-[4-(dimethylamino)phenyl]-N-(pyridin-2-ylmethyl)acrylamide 
• 1352550-03-8 (E)-2-cyano-3-(4-isopropylphenyl)-N-(pyridin-2-ylmethyl)acrylamide 

Relevant articles and documents

Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides

Malignant gliomas are the most common brain tumors, with generally dismal prognosis, early clinical deterioration and high mortality. Recently, 2-aminoquinoline scaffold derivatives have shown pronounced activity in central nervous system disorders. We herein reported a series of 2-aminoquinoline-3-carboxamides as novel non-alkylator anti-glioblastoma agents. The synthesized compounds showed comparable activity to cisplatin against glioblastoma cell line U87 MG in vitro. Among them, we found that 6a displayed good inhibitory activity against A172 and U118 MG glioblastoma cell lines and induced cell cycle arrest in the G2/M phase and apoptosis in U87 MG by flow cytometry analysis. Additionally, 6a displayed low cytotoxicity to several normal human cell lines. In silico study showed 6a had promising physicochemical properties and was predicted to cross the blood–brain barrier. Moreover, preliminary structure–activity relationships are also investigated, shedding light on further modifications towards more potent agents on this series of compounds. Our results suggest this compound has a promising potential as an anti-glioblastoma agent with a differential effect between tumor and non-malignant cells.

STILBENE AND FUSED STILBENE DERIVATIVES AS SOLAR CELL DYES

The present application discloses stilbene derivative compounds and phenyl- benzofuran compositions, useful in the manufacture of dye-sensitized solar cells and other similar technology.

BENZOFURAN DERIVATIVES FOR THE TREATMENT OF CNS AND OTHER DISORDERS

The present application discloses 2-phenyl benzofuran derivative compounds and compositions, and methods for treating ocular diseases, neurological disorders and protein aggregation-related disorders in patients using the compounds and compositions as dis